Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to US Adults with Heart Failure

Affiliations

• ¹ Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA USA; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA USA.
• ² Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA USA.
• ³ British Heart Foundation Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, UK.
• ⁴ National Heart Centre Singapore and Duke-National University of Singapore, Singapore.
• ⁵ Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI USA.
• ⁶ University Bicocca Milan, Italy, Papa Giovanni XXIII Hospital, Bergamo, Italy.
• ⁷ Northwestern University Feinberg School of Medicine, Chicago, IL USA.
• ⁸ University Medical Center Groningen, Groningen, Netherlands.
• ⁹ Université de Lorraine, Inserm Clinical Investigation Centre, CHU, Nancy, France.
• ¹⁰ Bayer plc, Research & Development, Pharmaceuticals, Reading, UK.
• ¹¹ Bayer, Research & Development, Pharmaceuticals, Whippany, NJ USA.
• ¹² Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA USA. Electronic address: mvaduganathan@bwh.harvard.edu.